

FOI Ref: 2022014- Contracting

I am requesting the following information in respect of:

- Diabetes (SMBG test strips/pen needles)
- Wound Care
- Urology

For each area:

1. The name(s) and direct contact email address(es) and direct telephone numbers of the person(s) in your Medicines Management team/CCG/Health Board who are responsible for the formulary

The CCG does not provide individual contact details for staff members. The medicines optimisation team can be contacted at:

calccgmedicinesmanagement@nhs.net.

2. The date of the next review of your formulary

- Diabetes (SMBG test strips/pen needles)

The review was due in July 2019. An interim review took place and was published in December 2019. The new formulary was expected to be complete by mid-2020. Whilst we recognise that the work is due, it is currently paused due to the COVID-19 Pandemic. We cannot give a specific date for an update as it depends on the availability of colleagues from various organisations in primary and secondary care.

- Wound Care

The current formulary can be accessed via the South West Yorkshire Area Prescribing Committee website <https://www.swyapc.org/wound-management-formulary/> . Due to the development of the West Yorkshire Health and Care Partnership, a West Yorkshire Area Prescribing Committee wound care sub-group is being re-developed but there is no current date available as to when this group will meet.

- Urology

Not applicable the CCG does not have a urology formulary.

3. Details of how you intend to review your formulary (include process, timelines)

- Diabetes (SMBG test strips/pen needles).

The Medicines Management team takes information sent in by companies and from a product search and, working with other stakeholders in secondary and primary care, do a review of all available products, considering our existing formulary as well. We produce the new formulary from that. Once the review starts it is normally completed within 3-4 months approximately.

- Wound Care

Due the re-development for the new wound group as described in answer 2, the process for formulary review is not yet agreed but likely to include stakeholder engagement, product assessment for safety, efficacy and cost effectiveness.

- Urology

Not applicable, see above.

4. Details of CCG/Health Board if part of a local partnership arrangement for formulary review. Please provide the contact's name, email address and telephone number for the person with responsibility where a partnership arrangement is in place

In the future the formulary reviews are likely to form part of the medicine's optimisation programme of the new West Yorkshire Health and Care partnership.